secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001437749-26-009081
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed Phase 2b DLB data show greater benefit in patients without AD co-pathology
--------------------------------------------------------------------------------

- At pTau181 <21 pg/mL, neflamapimod showed CDR-SB improvement of -1.11 vs placebo (p=0.005) in within-participant analysis.
- PK/PD analyses identified therapeutic trough concentration threshold of 4 ng/mL; DP Batch B achieved this in 75% of patients vs 50% for Batch A.
- Planned Phase 3 trial will use pTau181 <21 pg/mL enrichment, expecting 80-90% of patients without AD co-pathology.
- Data presented March 21, 2026 at AD/PD 2026 Conference in Copenhagen, Denmark.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926009081/0001437749-26-009081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926009081/crvo20260319_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-009081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer